# Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

> **NCT02498652** · PHASE2 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** RDEA3170 2.5 mg
- **DRUG:** allopurinol 300 mg

## Key facts

- **NCT ID:** NCT02498652
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-28
- **Primary completion:** 2015-11-19
- **Final completion:** 2016-06-02
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02498652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02498652, "Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02498652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*